AI Article Synopsis
- In developed countries, patients with hemophilia are now living nearly as long as those without the condition, increasing their risk for age-related diseases like cardiovascular issues.
- Managing heart disease in these patients is complex due to their heightened risk of bleeding.
- This report highlights a unique case of a man with moderate hemophilia B who had heart disease and arrhythmia, successfully treated with apixaban, left atrial appendage closure, and anti-hemorrhagic therapy.
Article Abstract
In developed countries, the life expectancy of patients with hemophilia (PwH) is now close to that of the unaffected male population. This means that these patients are at risk of developing age-related comorbidities, including cardiovascular disease. Managing cardiovascular disease in PwH patients can be particularly challenging, due to their high bleeding risk. To our knowledge, this is the first report of a male patient with moderate hemophilia B and hypertensive ischemic heart disease complicated by arrhythmia due to nonvalvular atrial fibrillation, who was treated with apixaban and left atrial appendage closure while receiving concomitant anti-hemorrhagic prophylaxis with eftrenonacog alfa.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8485731 | PMC |
| http://dx.doi.org/10.4081/hr.2021.9169 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!